Epigenetic mechanisms and cancer An interface between the environment and the genome

被引:157
|
作者
Herceg, Zdenko [1 ]
Vaissiere, Thomas [1 ]
机构
[1] Int Agcy Res Canc, Epigenet Grp, F-69372 Lyon, France
关键词
epigenome; environment; DNA methylation; lung cancer; biomarkers; ABERRANT DNA METHYLATION; DE-NOVO METHYLATION; CELL LUNG-CANCER; CPG ISLAND HYPERMETHYLATION; GENE PROMOTER METHYLATION; TUMOR-RELATED GENES; HISTONE MODIFICATIONS; S-ADENOSYLMETHIONINE; NORMAL-TISSUES; EARLY EVENT;
D O I
10.4161/epi.6.7.16262
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Although epidemiological studies support the role of the environment in a wide range of human cancers, the precise mechanisms by which environmental exposures promote cancer development and progression remain poorly understood. Environmental factors have been proposed to promote the development of malignancies by eliciting epigenetic changes; however, it is only with recent advances in epigenetics and epigenomics that target genes and the mechanisms underlying environmental influences are beginning to be elucidated. Because epigenetic mechanisms may function as an interface between environmental factors and the genome, deregulation of the epigenome by environmental stressors is likely to disrupt different cellular processes and contribute to cancer risk. In addition, the early appearance and ubiquity of epigenetic changes in virtually all steps of tumor development and progression in most, if not all, human neoplasms, make them attractive targets for biomarker discovery and targeted prevention. At the cellular level, aberrant epigenetic changes associated with environmental exposures may deregulate key cellular processes (including transcriptional control, DNA repair, cell cycle control and carcinogen detoxification), which can be further modulated by environmental stressors, thus defining not only the phenotype of the disease but also potential biomarkers. This review summarizes recent progress in our understanding of the epigenetic mechanisms through which environmental factors may promote tumor development, with a particular focus on human lung cancer.
引用
收藏
页码:804 / 819
页数:16
相关论文
共 50 条
  • [1] Epigenetic Mechanisms as an Interface Between the Environment and Genome
    Herceg, Zdenko
    HYPOXIA: TRANSLATION IN PROGRESS, 2016, 903 : 3 - 15
  • [2] Epigenetic mechanisms and genome stability
    Putiri, Emily L.
    Robertson, Keith D.
    CLINICAL EPIGENETICS, 2011, 2 : 299 - 314
  • [3] Dynamic epigenome as interface between environment and genome
    Szyf, M.
    MEDIZINISCHE GENETIK, 2009, 21 (01) : 7 - 13
  • [4] Epigenetic mechanisms and genome stability
    Emily L. Putiri
    Keith D. Robertson
    Clinical Epigenetics, 2011, 2 : 299 - 314
  • [5] Epigenetic alterations in cancer
    Ilango, Suganya
    Paital, Biswaranjan
    Jayachandran, Priyanka
    Padma, Palghat Raghunathan
    Nirmaladevi, Ramalingam
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2020, 25 : 1058 - 1109
  • [6] Epigenetic mechanisms in cancer
    Banerjee, Hirendra Nath
    Verma, Mukesh
    BIOMARKERS IN MEDICINE, 2009, 3 (04) : 397 - 410
  • [7] Epigenetic Mechanisms in Canine Cancer
    Xavier, Pedro Luiz Porfirio
    Mueller, Susanne
    Fukumasu, Heidge
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [8] Epigenetic mechanisms of breast cancer: an update of the current knowledge
    Karsli-Ceppioglu, Seher
    Dagdemir, Aslihan
    Judes, Gaelle
    Ngollo, Marjolaine
    Penault-Llorca, Frederique
    Pajon, Amaury
    Bignon, Yves-Jean
    Bernard-Gallon, Dominique
    EPIGENOMICS, 2014, 6 (06) : 651 - 664
  • [9] Epigenetic mechanisms of bone cancer pain
    Ni, Chaobo
    Chen, Liping
    Hua, Bohan
    Han, Zixin
    Xu, Longsheng
    Zhou, Qinghe
    Yao, Ming
    Ni, Huadong
    NEUROPHARMACOLOGY, 2024, 261
  • [10] Epigenetic regulation in cancer therapy: From mechanisms to clinical advances
    Tao, Lei
    Zhou, Yue
    Luo, Yuan
    Qiu, Jiahao
    Xiao, Yuzhou
    Zou, Jiao
    Zhang, Yu
    Liu, Xingchen
    Yang, Xinyu
    Gou, Kun
    Xu, Jing
    Guan, Xinqi
    Cen, Xiaobo
    Zhao, Yinglan
    MEDCOMM-ONCOLOGY, 2024, 3 (01):